May 5, 2020
Vifor Pharma’s partner Akebia with positive cardiovascular outcomes program testing vadadustat,
Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints.
Pharmaceuticals, Biotechnology and Life Sciences
Akebia’s vadadustat, an investigational oral HIF-PHI, achieves primary efficacy and cardiovascular safety endpoints.